All Stories

  1. First report of pathogenic SGCE variants in Mexican patients with myoclonus dystonia: A five-year follow-up study
  2. Manifestaciones neurológicas en la enfermedad del coronavirus 2019
  3. Neuropsychiatric profile of patients with craniocervical dystonia: A case-control study
  4. Editorial: Patient Empowerment and Person-Centered Care in Movement Disorders
  5. Independence of Coping Styles With the Patient–Doctor Relationship and Shared Decision-Making in People With Parkinson’s Disease
  6. Teaching neurology to “Millennials:” Basic concepts and recommendations
  7. Association Between Somatization and Nonmotor Symptoms Severity in People With Parkinson Disease
  8. Impulse Control Disorders, Impulsivity and Related Behaviors in Parkinson’s disease
  9. Review of Hereditary and Acquired Rare Choreas
  10. Factores asociados con deterioro cognitivo en una cohorte mexicana multicéntrica de Parkinson: estudio transversal comparativo
  11. Editorial to "Increases in institutionalization, healthcare resource utilization, and mortality risk associated with Parkinson disease psychosis: retrospective cohort study" by Friedman et al.
  12. Falls in persons with Parkinson's disease: Do non-motor symptoms matter as much as motor symptoms?
  13. Gait in Parkinson’s Disease
  14. Editorial: Impulse Control Disorders, Impulsivity and Related Behaviors in Parkinson's Disease
  15. Progressive supranuclear palsy as differential diagnosis of Parkinson's disease in the elderly
  16. Incidence rates of Parkinson’s disease in Mexico: Analysis of 2014-2017 statistics
  17. Terapias de infusión en la enfermedad de Parkinson avanzada
  18. The Parkinson's Disease Sleep Scale–2 (PDSS‐2): Validation of the Spanish Version and Its Relationship With a Roommate‐Based Version
  19. Brief historical review of Parkinson’s disease at 200 years of its description
  20. Low diagnostic accuracy of fragile X tremor/ataxia syndrome diagnostic criteria in late onset ataxia
  21. Diagnostic Utility of [11C]DTBZ Positron Emission Tomography In Clinically Uncertain Parkinsonism: Experience of a Single Tertiary Center
  22. Breve recorrido histórico de la enfermedad de Parkinson a 200 años de su descripción
  23. Huntington's disease-like disorders in Latin America and the Caribbean
  24. Motor and non-motor wearing-off and its impact in the quality of life of patients with Parkinson's disease
  25. Relationship between the MDS-UPDRS and Quality of Life: A large multicenter study of 3206 patients
  26. Beta-propeller-associated neurodegeneration can present with dominant or isolated parkinsonism
  27. Impulse control disorders in Parkinson's: Sleep disorders and nondopaminergic associations
  28. Brain oscillations reveal impaired novelty detection from early stages of Parkinson's disease
  29. Two-hundred Years Later: Is Parkinson�s Disease a Single Defined Entity?
  30. Premotor symptoms and the risk of Parkinson’s disease: A case-control study in Mexican population
  31. Treatable inherited rare movement disorders
  32. Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy
  33. Association of polymorphisms and reduced expression levels of the NR4A2 gene with Parkinson's disease in a Mexican population
  34. Spotlight on olfactory dysfunction in Parkinson's disease
  35. Who Can Diagnose Parkinson's Disease First? Role of Pre-motor Symptoms
  36. Differences in MDS-UPDRS Scores Based on Hoehn and Yahr Stage and Disease Duration
  37. Clinical Determinants of Parkinson's Disease-associated Pain Using the King's Parkinson's Disease Pain Scale
  38. Self-Assessment of Disability in Parkinson's Disease: The MDS-UPDRS Part II Versus Clinician-Based Ratings
  39. Living with chronic illness scale: international validation of a new self-report measure in Parkinson’s disease
  40. Analysis of four scales for global severity evaluation in Parkinson’s disease
  41. Satisfaction with Life Scale (SLS-6): First validation study in Parkinson's disease population
  42. Self-Perceived Pre-Motor Symptoms Load in Patients with Parkinson’s Disease: A Retrospective Study
  43. Frequency and clinical correlates of postural and striatal deformities in Parkinson’s disease
  44. Parkinson disease and progressive supranuclear palsy: protein expression in skin
  45. A systematic review and mixed treatment comparison of monotherapy in early Parkinson’s disease: implications for Latin America
  46. Visuospatial, visuoconstructive and visuoperceptive functioning in patients with Parkinson's disease
  47. Theory of the mind in subjects with Parkinson's disease: A case-control study
  48. Lack of Association between Impulse Control Disorders and REM Sleep Behavior Disorder in Patients with Parkinson’s Disease
  49. Convergent validation of EQ-5D-5L in patients with Parkinson's disease
  50. Delusional Parasitosis as a Treatment Complication of Parkinson Disease
  51. The P3a wave: A reliable neurophysiological measure of Parkinson’s disease duration and severity
  52. No Difference on Adherence Between Immediate-Release Versus Extended-Release Dopamine Agonists in Uninsured Subjects with Parkinson's Disease
  53. Impact of Neuropsychiatric Symptoms on the Quality of Life of Subjects with Parkinson’s Disease
  54. Electroconvulsive therapy in Parkinson´s disease
  55. Factores asociados a la calidad de vida de sujetos con enfermedad de Parkinson y a la carga en el cuidador
  56. Factors associated with the quality of life of subjects with Parkinson's disease and burden on their caregivers
  57. Prevalence and correlates of sleep disorders in Parkinson’s disease: a polysomnographic study
  58. Parkinson's disease severity levels and MDS-Unified Parkinson's Disease Rating Scale
  59. Change in Motor and Nonmotor Symptoms Severity in a “Real-Life” Cohort of Subjects with Parkinson’s Disease
  60. Relación entre el polimorfismo DRD2/ANKK1 y el desarrollo de complicaciones motoras en enfermedad de Parkinson
  61. A Polysomnographic Study of Parkinson’s Disease Sleep Architecture
  62. Cardiovascular variability in Mexican patients with Parkinson's disease
  63. Impulse control and related disorders in Mexican Parkinson's disease patients
  64. Comparing the accuracy of different smell identification tests in Parkinson’s disease: Relevance of cultural aspects
  65. Simultaneous Presentation of Ocular Flutter in Two Sisters
  66. Clinical, imaging, and molecular findings in a sample of Mexican families with pantothenate kinase-associated neurodegeneration
  67. Comparison of the Montreal Cognitive Assessment and Mini Mental State Examination Performance in Patients with Parkinson’s disease with w Low Educational Background
  68. Vas Eq-5d Utility Index In Parkinson’s Disease
  69. Direct Medical Costs Related To Parkinson’s Disease
  70. A Relationship Between Eq-5d Health State Classifications And Eq Vas Scores In Parkinson’s Disease
  71. A reappraisal of the ten steps test for identifying atypical parkinsonism
  72. Initial circulatory response to active standing in Parkinson's disease without typical orthostatic hypotension
  73. Genetic mutations in early-onset Parkinson's disease Mexican patients: Molecular testing implications
  74. Relationship between the MDS-UPDRS domains and the health-related quality of life of Parkinson's disease patients
  75. Low specificity and sensitivity of smell identification testing for the diagnosis of Parkinson?s disease
  76. Independent Validation of the SEND-PD and Correlation with the MDS-UPDRS Part IA
  77. Pan-American Consortium of Multiple System Atrophy (PANMSA). A Pan-American multicentre cohort study of Multiple System Atrophy
  78. Apathy and associated factors in Mexican patients with Parkinson’s disease
  79. The MDS-UPDRS Part II (motor experiences of daily living) resulted useful for assessment of disability in Parkinson's disease
  80. Assessing the non-motor symptoms of Parkinson's disease: MDS-UPDRS and NMS Scale
  81. Respuesta ortostática de la tensión arterial de pacientes con enfermedad de Parkinson inicial
  82. Clinical Determinants of Health-related Quality of Life in Mexican Patients with Parkinson’s Disease
  83. Prevalence and determinants of depression in Mexican patients with Parkinson's disease
  84. Overweight is more prevalent in patients with Parkinson's disease
  85. Opsoclonus Myoclonus Syndrome associated with GQ1b Antibodies
  86. Caffeine drinking, cigarette smoking, and dopaminergic replacement therapy dose in Parkinson’s disease
  87. Expanded and independent validation of the Movement Disorder Society–Unified Parkinson’s Disease Rating Scale (MDS-UPDRS)
  88. High frequency of Parkin exon rearrangements in Mexican-mestizo patients with early-onset Parkinson's disease
  89. Pan-American Consortium of Multiple System Atrophy. Preliminary Report (P06.079)
  90. A prospective series of patients with hyperglycaemia-associated movement disorders
  91. Detección y manejo de síntomas no motores en la enfermedad de Parkinson: impacto en su prevalencia
  92. Relación entre el tipo y lado de inicio de la sintomatología motora con la frecuencia de síntomas no motores en la enfermedad de Parkinson
  93. Involuntary attention impairment in early Parkinson's disease: An event-related potential study
  94. Relationship between the type and side of motor symptoms with the prevalence of non-motor symptoms in Parkinson's disease
  95. Prevalence of non-motor dysfunction among Parkinson's disease patients from a tertiary referral center in Mexico City
  96. Low frequency of common LRRK2 mutations in Mexican patients with Parkinson's disease
  97. Use of smell test identification in Parkinson's disease in Mexico: A matched case-control study
  98. Association of a history of varicella virus infection with multiple sclerosis
  99. Uso clínico de autoanticuerpos en neurología